BAYER AG

SMART trial results presented at Kidney Week 2024 show semaglutide reduces UACR by -52.1% in nondiabetic CKD patients, with sustained effects post-treatment. No significant Cr-eGFR difference observed, but weight and waist circumference reduced. Study explores semaglutide's potential in kidney and cardiovascular care.

The Otc Medicine Market research report forecasts industry growth (2024-2032), highlighting key players like Novartis AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd., and Sanofi SA. It details market drivers, regional insights, and segmentation by type, form, distribution channel, application, target group, and region. The report aids strategic decision-making through SWOT, Porter's Five Forces, and Pestle analyses.

FLOW trial data at ASN Kidney Week 2024 shows semaglutide 1.0 mg (Ozempic) reduces major kidney disease events by 24% in type 2 diabetes and CKD patients, with HR 0.76 (95% CI, 0.66 to 0.88; P = .0003). Semaglutide also lowers all-cause mortality (HR, 0.80; 95% CI, 0.67 to 0.95), cardiovascular death (HR, 0.71; 95% CI, 0.56 to 0.89), and death of undetermined cause (HR, 0.62; 95% CI, 0.42 to 0.91).

Dr. Chen Li, CEO of Hua Medicine, received the 'C.C. Tan Life Science Industrialization Award' for his contributions to biopharmaceutical innovation, including the development of Dorzagliatin, the world's first Glucose Kinesin Activator for diabetes treatment.

Bayer exercises first option under 2019 collaboration with Dewpoint Therapeutics to license a heart disease program targeting DCM patients with specific genetic mutations. The partnership leverages Dewpoint’s biomolecular condensate platform and Bayer’s small molecule R&D expertise to develop treatments for cardiovascular and renal diseases. Dewpoint will receive upfront and milestone payments totaling $424 million, excluding royalties.

The global Rx-to-OTC switches market is projected to reach USD 66.5 billion by 2033, driven by consumer convenience, cost-effectiveness, and regulatory support.

AI is revolutionizing drug discovery, from designing molecules to predicting protein structures, significantly reducing costs and timelines. AI-derived drugs have shown higher success rates in clinical trials, with companies like Exscientia and Insilico Medicine leading the charge. Key AI technologies include machine learning, deep learning, NLP, and generative models, transforming stages from target identification to clinical trials. Challenges include data quality, validation, and integration, but the future promises more personalized medicine and effective treatments.

The U.S. OTC drugs market is projected to grow from USD 42.80 billion in 2024 to USD 53 billion by 2029, driven by high Rx drug costs and increased OTC approvals. Dermatology and tablets segments are expected to lead growth. Key players include Johnson & Johnson, Novartis, Bayer, Sanofi, and Pfizer.

AstraZeneca and Ionis' Wainzua, a treatment for ATTR polyneuropathy, is set for EU approval after EMA's CHMP positive opinion. Wainzua, already approved in the US and Canada, reduces TTR levels by 82% and slows neurological impairment progression. It is also being developed for ATTR cardiomyopathy and is seen as a key drug for AZ's CVRM unit. Wainzua competes with Alnylam's Onpattro and Amvuttra, and Pfizer's Vyndamax/Vyndaqel.